Anika Therapeutics (ANIK) vs Pro-Dex (PDEX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed Pro-Dex (PDEX) over the past year, gaining 108.1% versus a gain of 79.1%. Over five years, PDEX leads with a +142.0% price change compared with -53.8% for ANIK. Anika Therapeutics is the larger company by market cap ($257.4 million vs $201.1 million), about 1.3 times the size.
On valuation, Pro-Dex trades at a lower forward P/E (18.5x vs 20.2x for Anika Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | PDEX |
|---|---|---|
| Share price | $19.23 | $62.21 |
| Market cap | $257.35M | $201.14M |
| 1-day change | -1.54% | -0.94% |
| YTD return | +100.10% | +61.67% |
| 1-year return | +108.12% | +79.07% |
| 5-year return | -53.84% | +141.97% |
| P/E ratio (TTM) | — | 15.10 |
| Forward P/E | 20.24 | 18.51 |
| EPS (TTM) | $-0.23 | $4.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $77.00 |
| 52-week low | $8.67 | $23.47 |
| Distance from 52-week high | -15.95% | -19.21% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +19.60% | +18.95% |
| Average volume | 98.57K | 81.57K |
| Shares outstanding | 13.38M | 3.23M |
| Employees | 235 | 201 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed PDEX by 29.0 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About Pro-Dex
PDEX stock →Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide.
Health Care · Medical/Dental Instruments · 201 employees
ANIK vs PDEX FAQ
Which is bigger, Anika Therapeutics or Pro-Dex?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $257.35M compared with $201.14M for Pro-Dex (PDEX).
Which stock has performed better over the past year, ANIK or PDEX?
ANIK returned +108.12% over the past 12 months, compared with +79.07% for PDEX (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and Pro-Dex in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.